Skip to content

The effects of myo-Inositol (Inofolic) on female infertility

The effects of myo-Inositol (Inofolic) on female infertility

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20150706023084N29
Enrollment
60
Registered
2025-09-21
Start date
2025-06-22
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

female infertility. Female infertility

Interventions

Intervention 1: Intervention group: Includes 30 patients aged between 20-45 years who refer to hospitals of Islamic Azad University of Tehran and are diagnosed with apathy. After reviewing the study's

Sponsors

Islamic Azad University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Infertile women aged 20 to 45

Exclusion criteria

Exclusion criteria: Underlying conditions such as diabetes, high blood pressure, high cholesterol. Individuals with neurological or psychiatric disorders. individuals with high prolactin levels. individuals with a history of recurrent miscarriage.

Design outcomes

Primary

MeasureTime frame
Follicle size (diameter). Timepoint: Before the start of the intervention and 8 weeks after the end of the intervention. Method of measurement: Ultrasound.;Number of follicles. Timepoint: Before the start of the intervention and 8 weeks after the end of the intervention. Method of measurement: Ultrasound.;Number of matured follicles. Timepoint: Before the start of the intervention and 8 weeks after the end of the intervention. Method of measurement: Ultrasound.;Pregnancy chance. Timepoint: Before the start of the intervention and 8 weeks after the end of the intervention. Method of measurement: Blood test (B-hcg test) and ultrasound.;BHCG test. Timepoint: Before the start of the intervention and 8 weeks after the end of the intervention. Method of measurement: Blood test (BHCG test).

Secondary

MeasureTime frame
Fetal heart rate FHR. Timepoint: 8 weeks after the end of the intervention. Method of measurement: Ultrasound.;Miscarriage rate. Timepoint: 8 weeks after the end of the intervention. Method of measurement: Ultrasound and patient interview.;Luteinizing hormone [LH]. Timepoint: Before the intervention and 8 weeks after the completion of the intervention. Method of measurement: Blood test (measurement of LH hormone by immunoassay method).;Follicle-stimulating hormone [FSH]. Timepoint: Before the intervention and 8 weeks after the completion of the intervention. Method of measurement: Blood test (FSH hormone measurement by immunoassay method).;Estrogen. Timepoint: Before the intervention and 8 weeks after the completion of the intervention. Method of measurement: Blood test (estrogen measurement by immunoassay).;Testosterone. Timepoint: Before the intervention and 8 weeks after the completion of the intervention. Method of measurement: Blood test (Testosterone measurement by immunoassay).;Androstenedione. Timepoint: Before the intervention and 8 weeks after the completion of the intervention. Method of measurement: Blood test (measurement of androstenedione by immunoassay).;Ovary size. Timepoint: Before the intervention and 8 weeks after the completion of the intervention. Method of measurement: Ultrasound.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Maryam Shiehmorteza

Islamic Azad University

shiehmorteza@iaups.ac.ir+98 21 2264 0052

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026